NCT00314236

Brief Summary

This study will investigate whether the treatment of damaged cartilage in the knee with BST-CarGel will increase the amount and quality of cartilage repair tissue when compared with microfracture alone. Furthermore, the effect of BST-CarGel in decreasing cartilage related pain and improving cartilage-related function in the knee will be assessed.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2005

Longer than P75 for not_applicable

Geographic Reach
3 countries

18 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2005

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

April 11, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 13, 2006

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2011

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2011

Completed
4.6 years until next milestone

Results Posted

Study results publicly available

December 18, 2015

Completed
Last Updated

December 18, 2015

Status Verified

December 1, 2015

Enrollment Period

5.2 years

First QC Date

April 11, 2006

Results QC Date

November 5, 2015

Last Update Submit

December 17, 2015

Conditions

Keywords

Cartilage repairCartilageKneeKnee PainMicrofracturearthroscopybone marrow stimulationChondrogenesisScaffoldChitosanA02.165.165A10.165.382.332G07.574.500.325.377.625.180A10.165.382.400Articular Cartilage Repair

Outcome Measures

Primary Outcomes (2)

  • Degree of Filling of the Lesion by Repair Tissue at 12 Months Through MRI.

    Evaluate the efficacy of BST-CarGel® applied to a microfractured lesion as compared to microfracture alone on the degree of lesion filling of the study knee in subjects with symptomatic pain associated with cartilage damage using MRI scans. The MR images will be acquired using high resolution 3D cartilage imaging sequences, so-called cartilage morphology sequences.

    12 months

  • Repair Cartilage T2 Relaxation Time

    Evaluate the efficacy of BST-CarGel® applied to a microfractured lesion as compared to microfracture alone on the repair tissue quality of the study knee in subjects with symptomatic pain associated with cartilage damage using MRI T2 mapping. T2 maps are created by calculating the T2 relaxation times for repair tissue and cartilage plates for every voxel (picture element of a MRI scan containing the average signal information of a specific spatial location of the imaged body).

    12 months

Secondary Outcomes (2)

  • Change From Baseline for Knee-related Pain, Stiffness and Function at 12 Months (WOMAC Parts A, B, C)

    12 months

  • Frequency of Adverse Events Between Study Groups

    12 months

Study Arms (2)

Microfracture with BST-CarGel

EXPERIMENTAL

BST-CarGel applied to a Microfractured lesion in repair of focal articular cartilage lesions on the femoral condyle

Device: BST-CarGel with Microfracture

Microfracture without BST-CarGel

ACTIVE COMPARATOR

Microfractured lesion in repair of focal articular cartilage lesions on the femoral condyle

Procedure: Microfracture without BST-CarGel

Interventions

Microfracture performed with BST-CarGel added to the treated defect

Microfracture with BST-CarGel

Microfracture performed without BST-CarGel added to the treated defect.

Microfracture without BST-CarGel

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Between 18 and 55 years of age
  • Focal articular cartilage lesion on the medial femoral condyle
  • Grade 3 or 4 acute (traumatic) or chronic (degenerative) lesion
  • Stable knee

You may not qualify if:

  • Multiple lesions or kissing lesions
  • Clinically relevant compartment malalignment (\> 5 degrees)
  • Undergone ligament treatments in the affected knee within 2 years prior to trial
  • Inflammatory arthropathy, such as rheumatoid arthritis, systemic lupus, or active gout
  • Previous surgical cartilage treatments in the affected knee in the last 12 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (18)

Sports Medicine Centre - University of Calgary

Calgary, Alberta, T2N 1N4, Canada

Location

New West Sports Medicine

New Westminster, British Columbia, V3L 5P5, Canada

Location

Hospital at UBC

Vancouver, British Columbia, V6T 1Z3, Canada

Location

Pan Am Clinic

Winnipeg, Manitoba, R3M 3E4, Canada

Location

Orthopaedic and Sport Medicine Clinic of Nova Scotia

Halifax, Nova Scotia, B3H 4M2, Canada

Location

Entralogix Clinical Group Inc.

Newmarket, Ontario, V6T 2B5, Canada

Location

Sports Medicine Clinic - Carleton University

Ottawa, Ontario, K1S 5B6, Canada

Location

Sunnybrook Health Sciences Centre, Div. of Orthopaedic Surgery

Toronto, Ontario, M3N 3M5, Canada

Location

Hopital Charles LeMoyne

Greenfield Park, Quebec, J4V 2H1, Canada

Location

Hospital Sacré-Coeur de Montréal

Montreal, Quebec, H4J 1C5, Canada

Location

Centre Hospitalier Affilie Universitaire de Quebec et Hôpital Valcartier

Québec, Quebec, G1J 1Z4, Canada

Location

Seoul National University Hospital

Seoul, 110-744, South Korea

Location

Kyung Hee University Medical Center

Seoul, 130-702, South Korea

Location

Hospital Clinic i Provincial de Barcelona

Barcelona, Barcelona, 08036, Spain

Location

Hospital Universitario Gregorio Maraňón

Madrid, Madrid, 28034, Spain

Location

Hospital La Paz

Madrid, Madrid, Spain

Location

FREMAP Centro de Prevención y Rehabilitación

Majadahonda, Madrid, 28220, Spain

Location

Hospital Begona de Gijon

Gijón, Principality of Asturias, 33204, Spain

Location

Related Publications (4)

  • Hoemann CD, Hurtig M, Rossomacha E, Sun J, Chevrier A, Shive MS, Buschmann MD. Chitosan-glycerol phosphate/blood implants improve hyaline cartilage repair in ovine microfracture defects. J Bone Joint Surg Am. 2005 Dec;87(12):2671-2686. doi: 10.2106/JBJS.D.02536.

    PMID: 16322617BACKGROUND
  • Chevrier A, Hoemann CD, Sun J, Buschmann MD. Chitosan-glycerol phosphate/blood implants increase cell recruitment, transient vascularization and subchondral bone remodeling in drilled cartilage defects. Osteoarthritis Cartilage. 2007 Mar;15(3):316-27. doi: 10.1016/j.joca.2006.08.007. Epub 2006 Sep 26.

    PMID: 17008111BACKGROUND
  • Hoemann CD, Sun J, McKee MD, Chevrier A, Rossomacha E, Rivard GE, Hurtig M, Buschmann MD. Chitosan-glycerol phosphate/blood implants elicit hyaline cartilage repair integrated with porous subchondral bone in microdrilled rabbit defects. Osteoarthritis Cartilage. 2007 Jan;15(1):78-89. doi: 10.1016/j.joca.2006.06.015. Epub 2006 Aug 8.

    PMID: 16895758BACKGROUND
  • Stanish WD, McCormack R, Forriol F, Mohtadi N, Pelet S, Desnoyers J, Restrepo A, Shive MS. Novel scaffold-based BST-CarGel treatment results in superior cartilage repair compared with microfracture in a randomized controlled trial. J Bone Joint Surg Am. 2013 Sep 18;95(18):1640-50. doi: 10.2106/JBJS.L.01345.

MeSH Terms

Conditions

Knee InjuriesFractures, Stress

Condition Hierarchy (Ancestors)

Leg InjuriesWounds and InjuriesFractures, Bone

Results Point of Contact

Title
Alberto Restrepo, MD, Director of Medical and Clinical Affairs
Organization
Piramal Healthcare (Canada) Limited

Study Officials

  • William Stanish, MD

    Orthopaedic and Sport Medicine - Dalhousie University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 11, 2006

First Posted

April 13, 2006

Study Start

December 1, 2005

Primary Completion

February 1, 2011

Study Completion

May 1, 2011

Last Updated

December 18, 2015

Results First Posted

December 18, 2015

Record last verified: 2015-12

Locations